-+ 0.00%
-+ 0.00%
-+ 0.00%

Lyon: Continued positive views on China's biopharmaceutical industry preferred Cinda Biotech (01801) and Columbotai (06990)

Zhitongcaijing·11/18/2026 08:33:53
Listen to the news

The Zhitong Finance App learned that Lyon released a research report saying that the fundamentals of China's biopharmaceutical industry were superior to market sentiment when entering 2027. Continued clinical verification, improved profit delivery, and strong external licensing activities contrasted with weak liquidity and valuation.

The bank expects that major regulatory and clinical milestones will drive the next round of industry catalysts, while multinational pharmaceutical companies are expected to maintain strong demand for original Chinese innovation. Cinda Biotech (01801) and Collombo Biotech (06990) were selected as “outperforming the market”. The target prices were HK$152 and HK$626.4, respectively.

The bank said that due to sound fundamentals and reasonable valuations, as well as catalysts for clinical, regulatory and business development, it continues to have a positive view of the Chinese biopharmaceutical industry, is optimistic that Cinda Biotech has leading commercial execution, diversified pipelines and proven global innovation capabilities, and is optimistic about the global franchise potential of SAC-TMT under Columbotai Biotech and the prospects for multi-year profit growth.